A review of the research on the cardiovascular risk factors and treatment options for Type II diabetic patients

The rise in the prevalence of diabetes is attributed to changes in human behavior, environment, and lifestyle. The prolonged survival of diabetes patients has been made possible by better care, but this is accompanied by chronic long-term problems brought on by hyperglycemia. Diabetes-related conditions like ketoacidosis or hypoglycemia are fewer common causes of death for diabetics than cardiovascular disease (CVD). Cardiovascular disease is more common in diabetes patients by a factor of 2 to 6 compared to the general population. Additionally, diabetics with CVD have a worse prognosis for survival than those with CVD who don't have diabetes, and their quality of life also declines. As a result, diabetes has been compared to a non-diabetic patient who has a history of heart disease in terms of risk. Identifying patients with a high risk of developing CVD can help prevent or delay cardiovascular events. Chemists must closely monitor these issues to manage CVD prevention and related ones. Patients taking aspirin and clopidogrel for an extended period should be constantly monitored due to the possibility of resistance. Guidelines have been developed to monitor and manage aspirin and clopidogrel in CVD preventive therapy.